NCT05036577 A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL Status COMPLETED Phase PHASE1
NCT05032183 Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Status TERMINATED Phase PHASE1/PHASE2
NCT05025800 ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05023980 A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05004064 Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04998669 Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma Status RECRUITING Phase PHASE2
NCT04989491 Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft Status RECRUITING Phase PHASE4
NCT04980222 A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04978584 Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04974996 A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) Status WITHDRAWN Phase PHASE1
NCT04974216 Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04965493 A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04934579 Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma Status COMPLETED Phase PHASE2
NCT04933617 Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Status TERMINATED Phase PHASE1
NCT04920968 Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL" Status RECRUITING Phase PHASE2
NCT04914741 A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04913103 Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL Status NOT_YET_RECRUITING Phase PHASE2
NCT04899570 Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma Status UNKNOWN Phase PHASE2
NCT04884035 Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1